The hydrazine antidepressants are a group of non-selective, irreversible monoamine oxidase inhibitors (MAOIs) which were discovered and initially marketed in the 1950s and 1960s. Most have been withdrawn due to toxicity, namely hepatotoxicity, but a few still remain in clinical use. Tranylcypromine, a structurally unrelated MAOI introduced around the same time as the hydrazines, was originally advertised as non-hydrazine as a result of its diminished propensity for causing hepatotoxicity.
List of hydrazine antidepressants
Marketed
Legend: ‡ = Withdrawn from the market; † = Partially discontinued; Bolded names indicate major drugs.
Never marketed Carbenzide Cimemoxin Domoxin Metfendrazine
Parkinson's Carbidopa
Tranquillosedative Centazolone
References
López-Muñoz F, Alamo C (2009). "Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today". Current Pharmaceutical Design. 15 (14): 1563–86. doi:10.2174/138161209788168001. PMID 19442174.


